导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.15% | 3996/4773 |
| 近一周 | -2.21% | 1501/5462 |
| 近一月 | -6.60% | 3582/5421 |
| 近一季 | -2.85% | 1313/5209 |
| 近半年 | -16.48% | 4080/4920 |
| 近一年 | -16.50% | 3794/4366 |
| 近两年 | 43.97% | 1692/2954 |
| 近三年 | -0.08% | 1930/2253 |
| 成立以来 | -42.09% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.19% 3777/4961 |
-3.06% 3436/5312 |
- - |
- - |
| 2025 | 13.50% 2640/4813 |
5.65% 754/3635 |
-0.06% 2798/4076 |
16.35% 2661/4524 |
-7.61% 3817/4813 |
| 2024 | 7.04% 1696/3463 |
-6.79% 2083/2808 |
-13.30% 2629/3014 |
19.55% 834/3129 |
10.80% 250/3463 |
| 2023 | 4.51% 226/2656 |
32.19% 65/2280 |
-5.85% 1546/2385 |
-11.40% 2062/2515 |
-5.23% 1295/2655 |
| 2022 | -27.28% 1464/2207 |
-18.57% 1353/1919 |
-6.27% 1879/2016 |
-14.26% 1053/2113 |
11.14% 152/2208 |
| 2021 | -1.08% 779/1822 |
-11.85% 1142/1255 |
7.21% 691/1330 |
-0.16% 480/1466 |
4.84% 311/1822 |
| 2020 | 10.73% 834/1250 |
5.62% 53/1022 |
12.86% 658/1060 |
-4.32% 1095/1152 |
- - |
| 2019 | 43.09% 197/1092 |
43.46% 29/748 |
-8.73% 602/797 |
3.49% 249/844 |
5.59% 698/912 |
| 2018 | -28.01% 432/834 |
- - |
- - |
- - |
-12.66% 469/691 |
| 2017 | -5.72% 514/714 |
- - |
- - |
- - |
- - |
| 2016 | -26.18% 489/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中信保诚中证信息安全指数(LOF)A VS. 长安沪深300非周期A(740101) |